Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Journal: Lancet HIV

Volume: 

Issue: 

Year of Publication: 2022

Affiliated Institutions: 

Statistics

Citations :  2
Authors :  0

Identifiers

Doi : 10.1016/S2352-3018(22)00041-8
SSN : 

Study Population

Male,Female

Mesh Terms

Other Terms

Study Design

Study Approach

Country of Study

South Africa

Publication Country